Tharimmune (THAR) Competitors $1.25 -0.01 (-0.40%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. DARE, BTAI, FNCH, RLMD, MBRX, PMN, CMMB, NRSN, PASG, and HOTHShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Dare Bioscience (DARE), BioXcel Therapeutics (BTAI), Finch Therapeutics Group (FNCH), Relmada Therapeutics (RLMD), Moleculin Biotech (MBRX), Promis Neurosciences (PMN), Chemomab Therapeutics (CMMB), NeuroSense Therapeutics (NRSN), Passage Bio (PASG), and Hoth Therapeutics (HOTH). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors Dare Bioscience BioXcel Therapeutics Finch Therapeutics Group Relmada Therapeutics Moleculin Biotech Promis Neurosciences Chemomab Therapeutics NeuroSense Therapeutics Passage Bio Hoth Therapeutics Dare Bioscience (NASDAQ:DARE) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Does the media favor DARE or THAR? In the previous week, Dare Bioscience had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for Dare Bioscience and 0 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.33 beat Dare Bioscience's score of -0.50 indicating that Tharimmune is being referred to more favorably in the news media. Company Overall Sentiment Dare Bioscience Negative Tharimmune Neutral Is DARE or THAR more profitable? Dare Bioscience's return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets Dare BioscienceN/A N/A -8.14% Tharimmune N/A -489.33%-264.34% Which has higher valuation & earnings, DARE or THAR? Dare Bioscience has higher revenue and earnings than Tharimmune. Dare Bioscience is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDare Bioscience$10K1,733.76-$4.05M-$0.17-11.29TharimmuneN/AN/A-$12.20M-$7.88-0.16 Which has more risk & volatility, DARE or THAR? Dare Bioscience has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Do analysts recommend DARE or THAR? Dare Bioscience presently has a consensus target price of $12.00, indicating a potential upside of 525.00%. Tharimmune has a consensus target price of $17.00, indicating a potential upside of 1,277.63%. Given Tharimmune's stronger consensus rating and higher probable upside, analysts plainly believe Tharimmune is more favorable than Dare Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders and institutionals have more ownership in DARE or THAR? 6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 4.0% of Dare Bioscience shares are owned by company insiders. Comparatively, 10.0% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryDare Bioscience and Tharimmune tied by winning 7 of the 14 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.32M$2.97B$5.44B$9.61BDividend YieldN/A2.46%4.61%4.14%P/E Ratio-0.1616.9029.7524.84Price / SalesN/A314.42449.4898.68Price / CashN/A41.8536.4258.36Price / Book1.817.318.185.64Net Income-$12.20M-$54.43M$3.26B$265.68M7 Day Performance-0.48%-0.01%1.15%2.51%1 Month Performance-29.89%5.13%2.82%1.88%1 Year Performance-58.73%10.24%28.41%24.00% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune3.3027 of 5 stars$1.23-2.1%$17.00+1,277.6%-53.0%$5.32MN/A-0.162DAREDare Bioscience1.3035 of 5 stars$2.26-5.8%$12.00+431.0%-36.8%$20.41M$25.91K-13.2930Upcoming EarningsBTAIBioXcel Therapeutics4.0243 of 5 stars$3.32+11.8%$42.60+1,183.1%-76.6%$20.12M$2.27M-0.2590Upcoming EarningsGap UpHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.43+1.1%N/A+288.9%$19.96MN/A-1.41190Gap DownRLMDRelmada Therapeutics4.5277 of 5 stars$0.60+5.3%$5.00+734.7%-81.4%$19.88MN/A-0.2410News CoverageNegative NewsEarnings ReportMBRXMoleculin Biotech2.6299 of 5 stars$0.66-4.2%$4.00+510.0%-69.2%$19.81MN/A0.0020Upcoming EarningsShort Interest ↑PMNPromis Neurosciences1.9926 of 5 stars$0.59-11.9%$4.33+634.5%-60.4%$19.29MN/A-11.805News CoverageUpcoming EarningsCMMBChemomab Therapeutics2.1049 of 5 stars$0.98+1.0%$8.50+767.3%-3.0%$18.48MN/A-1.2920Gap UpNRSNNeuroSense Therapeutics2.0351 of 5 stars$1.34-2.9%$14.00+944.8%+96.2%$18.32MN/A-2.4810PASGPassage Bio3.3852 of 5 stars$5.66-2.6%$150.00+2,550.2%-65.6%$17.66MN/A-0.28130News CoverageUpcoming EarningsHOTHHoth Therapeutics2.3345 of 5 stars$1.32-4.3%$4.00+203.0%+111.9%$17.44MN/A-1.164 Related Companies and Tools Related Companies Dare Bioscience Competitors BioXcel Therapeutics Competitors Finch Therapeutics Group Competitors Relmada Therapeutics Competitors Moleculin Biotech Competitors Promis Neurosciences Competitors Chemomab Therapeutics Competitors NeuroSense Therapeutics Competitors Passage Bio Competitors Hoth Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free THAR Stock Alerts